文献速递流行病学与生物统计真实世界研究与卫生经济

2型糖尿病药物试验纳入系统评价的时机与频率与试验特征相关

The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics.
PubMed 文献 · J Clin Epidemiol · 2019-01-30

该研究纳入2007至2017年系统评价中的668项2型糖尿病药物试验,分析试验特征与纳入速度及频率的关联。结果显示中位纳入时间76.1周,中位纳入频率3次;产业资助、样本量更大、阳性结论及高影响因子期刊发表的试验纳入更快或更频繁。

要点

  • 产业资助试验纳入系统评价更快且更频繁
  • 样本量更大及高影响因子期刊试验纳入更快更频繁
  • 阳性结论试验纳入频率更高

核心结论

  • 特定试验特征与2型糖尿病系统评价中试验纳入更快或更频繁相关。

研究设计与样本

  • 研究分析了2007年1月1日至2017年1月1日发表的系统评价中纳入的668项试验。
  • 采用多变量Cox比例风险模型和回归模型量化关联。

主要发现

  • 668项试验的中位纳入时间为76.1周,中位纳入频率为3次。
  • 产业资助试验纳入时间更短(HR 1.39;95%CI 1.13-1.71)。
  • 样本量更大试验纳入时间更短(HR 1.26;95%CI 1.17-1.36)。
  • 高影响因子期刊试验纳入时间更短(HR 1.28;95%CI 1.14-1.45)。
  • 产业资助(RR 2.36;95%CI 2.11-2.64)、样本量更大(RR 1.51;95%CI 1.47-1.55)、阳性结论(RR 1.89;95%CI 1.68-2.13)及高影响因子期刊(RR 1.13;95%CI 1.08-1.18)与纳入频率更高相关。

临床怎么用

  • 系统评价者应关注产业资助、大样本及阳性结论试验可能更早更频繁被纳入的偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether certain trial characteristics are associated with faster or more frequent inclusion in systematic reviews for drug interventions in type 2 diabetes. STUDY DESIGN AND SETTING: We examined trials included in systematic reviews published between January 1, 2007 and January 1, 2017. Primary outcomes were time between trial publication and first inclusion in a systematic review and frequency of inclusion in systematic reviews over the study period. Multivariable Cox proportional hazards and regression models quantified associations with funding source, number of participants, trial conclusion, and journal impact factor. RESULTS: Among 668 trials, the median time to inclusion was 76.1 weeks. Time to inclusion was shorter for trials with industry funding (hazard ratio [HR] 1.39; 95% confidence interval [CI] 1.13-1.71), more participants (HR 1.26; 95% CI 1.17-1.36), and published in higher impact factor journals (HR 1.28; 95% CI 1.14-1.45). The median frequency of inclusion was three. Frequency of inclusion was greater for trials with industry funding (relative risk [RR] 2.36; 95% CI 2.11-2.64), more participants (RR 1.51; 95% CI 1.47-1.55), positive conclusions (RR 1.89; 95% CI 1.68-2.13), and published in higher impact factor journals (RR 1.13; 95% CI 1.08-1.18). CONCLUSION: Certain trial characteristics are associated with faster or more frequent trial inclusion in systematic reviews of type 2 diabetes.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Dunn AG, Orenstein L, Coiera E, et al. The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics. J Clin Epidemiol. 2019. PMID: 30708175. doi:10.1016/j.jclinepi.2019.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。